TheProfitWatch

TRVI - Trevi Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
10.66 0.35 (3.28%) -0.01 (-0.05%) -0.02 (-0.18%) -0.02 (-0.14%) 0.0 (0.0%) 0.42 (3.97%) --- 0.0 (0.0%)

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.09
Diluted EPS:
-0.09
Basic P/E:
-122.3333
Diluted P/E:
-122.3333
RSI(14) 1m:
56.25
VWAP:
11.01
RVol:

Events

Period Kind Movement Occurred At

Related News